Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigators Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
Study of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
Sponsor:Acerta Pharma BV
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS5165
U.S. Government ID:NCT03836261
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study, which involves research, is to determine if giving an experimental drug called acalabrutinib in combination with venetoclax with and without obinutuzumab is safe and effective for treating people with CLL compared to a combination of bendamustine and rituximab (BR) or a combination of Fludarabine, Cyclophosphamide and Rituximab (FCR).

Do You Qualify?
Are you 18 years of age or older?YesNo
Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL)?YesNo
Are you able to swallow capsules and tablets without difficulty?YesNo
Submit
Cancel
Investigator
Nicole Lamanna, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162